Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Public Genomics Data Needed, FDA, NIH Say; Patent Protection Still An Issue

Executive Summary

NIH expects its small molecule database to provide drug development candidates to small biotechnology firms and disease foundations pursuing orphan indications

You may also be interested in...



NIH Move To Consolidate Translational Programs Is Not The Big Shakeup It's Made Out To Be, Agency Says

The National Institutes of Health's proposed National Center for Advancing Translational Sciences reflects neither a shakeup of existing NIH programs nor any intent to create an agency that functions like a drug company, NIH officials say.

NIH Move To Consolidate Translational Programs Is Not The Big Shakeup It's Made Out To Be, Agency Says

The National Institutes of Health's proposed National Center for Advancing Translational Sciences reflects neither a shakeup of existing NIH programs nor any intent to create an agency that functions like a drug company, NIH officials say.

Biotechs Must Work With NIH To Tackle “Complexity,” NIH Director Tells BIO

Pharmaceutical and biotech companies need to work with NIH to put new research tools into the public domain, National Institutes of Health Director Elias Zerhouni, MD, told the recent Biotechnology Industry Organization investor conference in New York

Related Content

UsernamePublicRestriction

Register

PS042848

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel